Apigenin as an emerging hepatoprotective agent: current status and future perspectives

被引:3
作者
Wang, Cheng [1 ,2 ]
Feng, Xiaoli [1 ,3 ]
Li, Wen [1 ,2 ]
Chen, Li [1 ,2 ]
Wang, Xinming [1 ,2 ]
Lan, Yimiao [1 ,2 ]
Tang, Rong [4 ]
Jiang, Ting [1 ,2 ]
Zheng, Lingli [1 ,2 ]
Liu, Gang [1 ,2 ]
机构
[1] Chengdu Med Coll, Sch Clin Med, Chengdu, Peoples R China
[2] Chengdu Med Coll, Dept Pharm, Affiliated Hosp 1, Chengdu, Peoples R China
[3] Chengdu Med Coll, Dept Resp & Crit Care Med, Affiliated Hosp 1, Chengdu, Peoples R China
[4] Sichuan Univ, Coll Foreign Languages & Cultures, Chengdu, Peoples R China
关键词
apigenin; liver disease; hepatoprotection; toxicity; pharmacokinetics; new formulations; INDUCED LIVER-INJURY; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; PPAR-GAMMA; CARBON-TETRACHLORIDE; SOLID DISPERSIONS; INDUCED APOPTOSIS; UP-REGULATION; IN-VITRO; HEPATOTOXICITY;
D O I
10.3389/fphar.2024.1508060
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Apigenin (C15H10O5, API) is a natural flavonoid widely found in vegetables, fruits, and plants such as celery, oranges, and chamomile. In recent years, API has attracted considerable attention as a dietary supplement due to its low toxicity, non-mutagenic properties and remarkable therapeutic efficacy in various diseases. In particular, evidence from a large number of preclinical studies suggests that API has promising effects in the prevention and treatment of a variety of liver diseases, including multifactorial liver injury, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, liver fibrosis and liver cancer. This paper provides a comprehensive review of the progress of research into the therapeutic applications of API in liver diseases as of August 2024, based on literature retrieved from databases such as Web of Science, PubMed, CNKI, Google Scholar and ScienceDirect. The hepatoprotective effects of API involve multiple molecular mechanisms, including inhibition of inflammation, alleviation of hepatic oxidative stress, amelioration of insulin resistance, promotion of fatty acid oxidation, inhibition of liver cancer cell proliferation and differentiation, and induction of tumour cell apoptosis. More importantly, signaling pathways such as Nrf2, NF-kappa B, PI3K/Akt/mTOR, NLRP3, Wnt/beta-catenin, TGF-beta 1/Smad3, AMPK/SREBP, PPAR alpha/gamma, MAPKs, and Caspases are identified as key targets through which API exerts its beneficial effects in various liver diseases. Studies on its toxicity and pharmacokinetics indicate that API has low toxicity, is slowly metabolized and excreted in vivo, and has low oral bioavailability. In addition, the paper summarises and discusses the sources, physicochemical properties, new dosage forms, and current challenges and opportunities of API, with the aim of providing direction and rationale for the further development and clinical application of API in the food, pharmaceutical and nutraceutical fields.
引用
收藏
页数:31
相关论文
共 208 条
[101]   Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies [J].
Liu, Yu-Chin ;
Yeh, Chau-Ting ;
Lin, Kwang-Huei .
CELLS, 2020, 9 (06)
[102]   Apigenin reduces the excessive accumulation of lipids induced by palmitic acid via the AMPK signaling pathway in HepG2 cells [J].
Lu, Jing ;
Meng, Zhuoqun ;
Cheng, Bijun ;
Liu, Meitong ;
Tao, Siyu ;
Guan, Shuang .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (04) :2965-2971
[103]   Apigenin attenuates atherosclerosis and non-alcoholic fatty liver disease through inhibition of NLRP3 inflammasome in mice [J].
Lu, Zheng ;
Liu, Lu ;
Zhao, Shunxin ;
Zhao, Jiangtao ;
Li, Sujun ;
Li, Mingyang .
SCIENTIFIC REPORTS, 2023, 13 (01)
[104]  
Lv C., 2016, Biodistribution of apigenin nanosuspension and its pharmacodynamics studies on anti-liver cancer in vivo and vitro
[105]   Apigenin ameliorates HFD-induced NAFLD through regulation of the XO/NLRP3 pathways [J].
Lv, Yanan ;
Gao, Xiaona ;
Luo, Yan ;
Fan, Wentao ;
Shen, Tongtong ;
Ding, Chenchen ;
Yao, Ming ;
Song, Suquan ;
Yan, Liping .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2019, 71 :110-121
[106]  
Ma D. X., 2019, Study on the mechanism of apigenin against nonalcoholic fatty liver disease
[107]   Alcohol-associated liver disease [J].
Mackowiak, Bryan ;
Fu, Yaojie ;
Maccioni, Luca ;
Gao, Bin .
JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (03)
[108]   Apigenin, a dietary flavonoid, induces apoptosis, DNA damage, and oxidative stress in human breast cancer MCF-7 and MDA MB-231 cells [J].
Madunic, Ivana Vrhovac ;
Madunic, Josip ;
Antunovic, Maja ;
Paradzik, Mladen ;
Garaj-Vrhovac, Vera ;
Breljak, Davorka ;
Marijanovic, Inga ;
Gajski, Goran .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2018, 391 (05) :537-550
[109]   Apigenin: A dietary flavonoid with diverse anticancer properties [J].
Madunic, Josip ;
Madunic, Ivana Vrhovac ;
Gajski, Goran ;
Popic, Jelena ;
Garaj-Vrhovac, Vera .
CANCER LETTERS, 2018, 413 :11-22
[110]   Experimental models of hepatotoxicity related to acute liver failure [J].
Maes, Michael ;
Vinken, Mathieu ;
Jaeschke, Hartmut .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2016, 290 :86-97